Hematopoiesis News Volume 2.26 | Jul 5 2011

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event During Human Lymphomagenesis
Researchers report that inactivation of Ten-Eleven-translocation (TET)2 gene in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autonomous manner, endows the cells with competitive advantage, and eventually leads to the development of malignancies. [Cancer Cell]

Adult Human Circulating CD34^–Lin^–CD45^–CD133^– Cells Can Differentiate into Hematopoietic and Endothelial Cells
To identify circulating precursors having the developmental potential of the hemangioblast, investigators established a new ex-vivo long-term culture model supporting the differentiation of both hematopoietic and endothelial cell lineages. [Blood]

Targeting Levels or Oligomerization of Nucleophosmin 1 Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1
Scientists determined the effects of targeting NPM1 in cultured and primary AML cells. [Blood]

Chronic IFNγ Production in Mice Induces Anemia by Reducing Erythrocyte Lifespan and Inhibiting Erythropoiesis through an IRF-1/PU.1-Axis
Researchers described a novel mouse model for anemia of chronic disease, in which enhanced CD27-mediated costimulation strongly increases the formation of IFNγ-producing effector T cells, leading to a progressive anemia. [Blood]

Down-Regulation of the RUNX1-Target Gene NR4A3 Contributes to Hematopoiesis Deregulation in Familial Platelet Disorder/Acute Myelogenous Leukemia (FPD/AML)
Investigators performed analysis of hematopoiesis from two FPD/AML pedigrees with two distinct RUNX1 germ line mutations, i.e. the R139X in a pedigree without AML and the R174Q mutation in a pedigree with AML. [Blood]

Orientation-Regulated Immobilization of Jagged1 on Glass Substrates for Ex Vivo Proliferation of a Bone Marrow Cell Population Containing Hematopoietic Stem Cells
In this study, the orientation-regulated immobilization of a Notch ligand was designed to achieve the efficient Notch ligand–receptor recognition for the ex vivo proliferation of a bone marrow cell population containing hematopoietic stem cells. [Biomaterials]

The Novel Compound OSI-461 Induces Apoptosis and Growth Arrest in Human Acute Myeloid Leukemia Cells
Researchers treated bone marrow derived CD34⁺ selected blast cells from 20 acute myeloid leukemia (AML) patients and the five AML cell lines KG-1a, THP-1, HL-60, U-937, and MV4-11 with the physiologically achievable concentration of 1 μM OSI-461 or equal amounts of DMSO as a control. [Ann Hematol]

CLINICAL RESEARCH

Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) Plus Idarubicin with or without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia
To determine whether cenersen merits testing in larger efficacy studies, an exploratory study of cenersen in combination with idarubicin either alone or with 1 of 2 doses of cytarabine was performed in first-salvage acute myeloid leukemia patients. [Cancer]

High-Dose Cytarabine Induction Is Well Tolerated and Active in Patients with De Novo Acute Myeloid Leukemia Older than 60 Years
The authors explored the safety and tolerability of a modified high-dose cytarabine induction regimen consisting of 6 daily doses of cytarabine at 2 g/m² in combination with 3 daily doses of daunorubicin at 45 mg/m² in 59 consecutive patients aged older than 60 years who had de novo acute myeloid leukemia diagnosed between July 1996 and February 2005. [Cancer]

Non-Steroidal Anti-Inflammatory Drug (NSAID) and Acetaminophen Use and Risk of Adult Myeloid Leukemia
In a population-based case-control study, investigators evaluated analgesic use among 670 newly diagnosed myeloid leukemia cases [including 420 acute myeloid leukemias and 186 chronic myeloid leukemias] and 701 controls aged 20-79 years. [Cancer Epidemiol Biomarkers Prev]

ABIM Elects Richard Stone, MD, Chair of its Subspecialty Board on Medical Oncology
Richard Stone, MD, Director of the Adult Acute Leukemia Program at Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, has been named Chair of the American Board of Internal Medicine’s (ABIM) Subspecialty Board on Medical Oncology. [American Board of Internal Medicine Press Release]

Ablynx Initiates a Phase I Study for ALX-0651, the First Nanobody in Clinical Development Targeting a GPCR
Ablynx announced that it has initiated a Phase I clinical trial in healthy volunteers with ALX-0651, an anti-CXCR4 Nanobody, for use in stem cell mobilization. [Ablynx Press Release]

Personalized Medicine on the Horizon for BC Cancer Patients
Genome British Columbia (BC) and the BC Cancer Foundation have joined forces to announce a major step forward in applying the power of genomics to personalized medicine. [Genome British Columbia Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Cold Spring Harbor – Cell Death
October 11-15, 2011
Cold Spring Harbor, United States

NEW American Association for Cancer Research International Conference New Horizons in Cancer Research: Biology to Prevention to Therapy
December 13-16, 2011
Gurgaon, India

Visit our events page to see a complete list of events in the hematopoietic community

Post Doctoral Fellow (MedImmune)

Laboratory Project Scientist (University of California, San Diego)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.